Abstract： Objective： To observe the clinical effect of modified Lishi Jiedu Decoction combined with Recombinant Human Interferon α- 2B Gel for high- risk human papillomavirus(HPV) infection. Methods：A total of 80 cases of patients with high-risk HPV infection were selected and divided into the treatment group and the control group according to the random number table method， with 40 cases in each group. The control group was treated with Recombinant Human Interferon α- 2B Gel， and the treatment group was additionally treated with modified Lishi Jiedu Decoction based on the treatment of the control group. Both groups were treated for two months. The negative conversion rates of HPV，syndrome scores of dampness toxin stagnation syndrome and clinical effects in the two groups were compared. Results： The total effective rate was 90.63% in the treatment group and 65.63% in the control group，the difference being significant(P＜0.05). The negative conversion rate of HPV was 92.50% in the treatment group，significantly higher than that of 72.50% in the control group， the difference being significant(P＜0.05). Before treatment， there was no significant difference being found in the comparison of syndrome scores of dampness toxin stagnation syndrome including large leukorrhea amount， leukorrheal abnormal flavor， distending pain in lower abdomen，scanty dark urine and dry stool between the two groups(P＞0.05)；after treatment， the above syndrome scores in the two groups were decreased when compared with those before treatment(P＜0.05)， and the scores in the treatment group were lower than those in the control group(P＜0.05). Conclusion：Modified Lishi Jiedu Decoction combined with Recombinant Human Interferon α-2B Gel for high-risk HPV infection can improve negative conversion rates of virus，and further improve tradititonal Chinese medicine syndromes with better clinical effects.